Probiotics: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
===== | ===Lacticaseibacillus rhamnosus GG (LGG) — Antibiotic-Associated Diarrhea=== | ||
[https://pubmed.ncbi.nlm.nih.gov/29511547/ | Researchers | Journal of Clinical Gastroenterology | 2018] | |||
A network meta-analysis involving more than 9,000 participants compares different probiotics for prevention of antibiotic-associated diarrhea. Lactobacillus rhamnosus GG had the highest probability of ranking among the most effective and best-tolerated probiotic interventions. | |||
[https://pubmed.ncbi.nlm.nih.gov/30078376/ | V. Agamennone et al. | European Journal of Clinical Pharmacology | 2018] | |||
[https:// | A strain-specific analysis of probiotic preparations used to prevent antibiotic-associated diarrhea identifies seven effective formulations. Lactobacillus rhamnosus GG produced one of the strongest effects, with substantially less antibiotic-associated diarrhea than placebo. | ||
[https://pubmed.ncbi.nlm.nih.gov/28827186/ | C. Mantegazza et al. | Nutrients | 2018] | |||
[https:// | A clinical review of probiotics for pediatric antibiotic-associated diarrhea finds the strongest strain-specific evidence for Lactobacillus rhamnosus GG and Saccharomyces boulardii. The authors emphasize that results obtained with these strains should not be generalized to other probiotics. | ||
[https://pubmed.ncbi.nlm.nih.gov/26756877/ | Hania Szajewska et al. | Journal of Pediatric Gastroenterology and Nutrition | 2016] | |||
[https:// | Evidence-based recommendations from the European Society for Pediatric Gastroenterology, Hepatology and Nutrition identify Lactobacillus rhamnosus GG as one of the probiotic strains with sufficient evidence to recommend for preventing antibiotic-associated diarrhea in children. | ||
[https://pubmed.ncbi.nlm.nih.gov/26365389/ | Hania Szajewska and Marek Kołodziej | Alimentary Pharmacology & Therapeutics | 2015] | |||
[https:// | A strain-specific systematic review and meta-analysis evaluates Lactobacillus rhamnosus GG, commonly abbreviated LGG, for prevention of antibiotic-associated diarrhea. LGG significantly reduced antibiotic-associated diarrhea in children and adults, although the certainty of evidence was rated moderate to low. This is one of the better-supported strain-specific uses of probiotics. | ||
[https://pubmed.ncbi.nlm.nih.gov/24889895/ | Lynne V. McFarland | Annals of Nutrition and Metabolism | 2015] | |||
[https:// | A strain-specific review of probiotics for pediatric antibiotic-associated diarrhea finds significant preventive effects for Lactobacillus rhamnosus GG as well as Saccharomyces boulardii. | ||
[https://pubmed.ncbi.nlm.nih.gov/16113542/ | Jason Hawrelak et al. | Digestive Diseases and Sciences | 2005] | |||
[https:// | A systematic review evaluates Lactobacillus rhamnosus GG specifically for preventing antibiotic-associated diarrhea. Four of six qualifying clinical trials reported a significant reduction in diarrhea risk, while another showed fewer days with antibiotic-associated diarrhea. | ||
===== | ===Saccharomyces boulardii — Antibiotic-Associated Diarrhea=== | ||
[https://pubmed.ncbi.nlm.nih.gov/33844181/ | M. Storr et al. | Medizinische Klinik | 2021] | |||
[https:// | A clinical review emphasizes that prevention of antibiotic-associated diarrhea is strain-specific. The authors identify Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG as evidence-based options rather than recommending probiotics as a general category. | ||
[https://pubmed.ncbi.nlm.nih.gov/26216624/ | Hania Szajewska and Marek Kołodziej | Alimentary Pharmacology & Therapeutics | 2015] | |||
[https:// | A systematic review and meta-analysis evaluates the probiotic yeast Saccharomyces boulardii specifically for antibiotic-associated diarrhea. Supplementation significantly reduced the risk of antibiotic-associated diarrhea among both children and adults. | ||
[https://pubmed.ncbi.nlm.nih.gov/20458757/ | Lynne V. McFarland | World Journal of Gastroenterology | 2010] | |||
[https:// | A large systematic review examines Saccharomyces boulardii across multiple gastrointestinal disorders. Twenty-seven randomized controlled studies involving more than 5,000 participants were analyzed, with particularly strong evidence for prevention of antibiotic-associated diarrhea. | ||
[https://pubmed.ncbi.nlm.nih.gov/16635227/ | Lynne V. McFarland | American Journal of Gastroenterology | 2006] | |||
[https:// | A meta-analysis evaluates probiotics for antibiotic-associated diarrhea and Clostridium difficile disease. Saccharomyces boulardii and Lactobacillus rhamnosus GG were among the probiotic interventions significantly associated with prevention of antibiotic-associated diarrhea. | ||
[https://pubmed.ncbi.nlm.nih.gov/16128673/ | Hania Szajewska and Jacek Mrukowicz | Alimentary Pharmacology & Therapeutics | 2005] | |||
[https:// | A strain-focused meta-analysis of randomized controlled trials finds Saccharomyces boulardii moderately effective for preventing antibiotic-associated diarrhea in children and adults. | ||
[https://pubmed.ncbi.nlm.nih.gov/15740542/ | M. Kotowska et al. | Alimentary Pharmacology & Therapeutics | 2005] | |||
[https:// | A randomized placebo-controlled trial evaluates Saccharomyces boulardii for preventing antibiotic-associated diarrhea in children. Children receiving the probiotic developed substantially less antibiotic-associated diarrhea than those receiving placebo. | ||
===== | ===Limosilactobacillus reuteri DSM 17938 — Infantile Colic=== | ||
[https://pubmed.ncbi.nlm.nih.gov/29279326/ | Valerie Sung et al. | Pediatrics | 2018] | |||
[https:// | An individual-participant-data meta-analysis evaluates Lactobacillus reuteri DSM 17938 specifically for infantile colic. DSM 17938 reduced crying duration and increased treatment response among breastfed infants. Evidence was insufficient to reach the same conclusion for formula-fed infants. | ||
An | |||
[https://pubmed.ncbi.nlm.nih.gov/29390535/ | P. Gutiérrez-Castrellón et al. | Medicine | 2017] | |||
[https:// | A network meta-analysis compares treatments for infantile colic. Lactobacillus reuteri DSM 17938 was among the interventions associated with meaningful reductions in infant colic symptoms. | ||
[https://pubmed.ncbi.nlm.nih.gov/25444531/ | K. Chau et al. | Journal of Pediatrics | 2015] | |||
[https:// | A randomized double-blind placebo-controlled Canadian trial finds that Lactobacillus reuteri DSM 17938 significantly reduces crying and fussing among breastfed infants with colic. | ||
[https://pubmed.ncbi.nlm.nih.gov/25876529/ | G. L. Mi et al. | PLoS ONE | 2015] | |||
[https:// | A randomized trial examines Lactobacillus reuteri DSM 17938 for infantile colic. Supplementation reduced daily crying duration and was associated with higher parental satisfaction compared with the control treatment. | ||
[https://pubmed.ncbi.nlm.nih.gov/22981952/ | Hania Szajewska et al. | Journal of Pediatrics | 2013] | |||
[https:// | A randomized controlled trial evaluates Lactobacillus reuteri DSM 17938 in exclusively or predominantly breastfed infants with colic. Infants receiving DSM 17938 experienced greater reductions in crying time than those receiving placebo. | ||
[https://pubmed.ncbi.nlm.nih.gov/20713478/ | Francesco Savino et al. | Pediatrics | 2010] | |||
[https:// | A randomized controlled trial administers Lactobacillus reuteri DSM 17938 to breastfed infants with colic. A dose of 100 million CFU per day reduced crying and improved colic symptoms compared with placebo. | ||
=== | ===Bifidobacterium longum 35624 — IBS=== | ||
[https://pubmed.ncbi.nlm.nih.gov/41682832/ | R. Maslennikov et al. | PubMed | 2026] | |||
[https:// | A strain-specific systematic review and meta-analysis identifies Bifidobacterium longum 35624, formerly classified as Bifidobacterium infantis 35624, among the individual probiotic strains showing efficacy for important IBS symptoms. | ||
[https://pubmed.ncbi.nlm.nih.gov/19367213/ | Darren M. Brenner et al. | Reviews in Gastroenterological Disorders | 2009] | |||
[https:// | A focused review examines Bifidobacterium infantis 35624 as a treatment for IBS. Two randomized controlled trials had demonstrated improvements in individual and global IBS symptoms without an apparent increase in adverse events. | ||
[https://pubmed.ncbi.nlm.nih.gov/19277023/ | Darren M. Brenner et al. | American Journal of Gastroenterology | 2009] | |||
[https:// | A systematic review of probiotics for IBS identifies Bifidobacterium infantis 35624 as one of the strains supported by appropriately designed randomized controlled studies. Trials reported improvements in abdominal pain, bloating, and bowel-related symptoms. | ||
[https://pubmed.ncbi.nlm.nih.gov/16863564/ | Peter J. Whorwell et al. | American Journal of Gastroenterology | 2006] | |||
[https:// | A large randomized controlled trial evaluates Bifidobacterium infantis 35624 in women with irritable bowel syndrome. One tested dose significantly improved abdominal pain, bloating, bowel dysfunction, incomplete evacuation, straining, and global IBS symptoms compared with placebo. | ||
[https://pubmed.ncbi.nlm.nih.gov/15765388/ | Liam O’Mahony et al. | Gastroenterology | 2005] | |||
[https:// | A randomized clinical trial compares Bifidobacterium infantis 35624 with another probiotic and placebo in IBS. Strain 35624 improved IBS symptoms and was associated with normalization of a measure of pro- versus anti-inflammatory immune signaling. | ||
=== | ===Lactiplantibacillus plantarum 299v (DSM 9843) — IBS=== | ||
[https://pubmed.ncbi.nlm.nih.gov/33556972/ | H. Krammer et al. | Zeitschrift für Gastroenterologie | 2021] | |||
[https:// | A clinical study evaluates Lactobacillus plantarum 299v for irritable bowel syndrome. Treatment was associated with significant improvement in global IBS symptoms and quality of life. | ||
[https://pubmed.ncbi.nlm.nih.gov/25194614/ | C. Stevenson et al. | Nutrition | 2014] | |||
[https:// | A randomized trial provides an important counterpoint to positive studies of strain 299v. Eight weeks of Lactobacillus plantarum 299v did not significantly improve abdominal pain or bloating compared with placebo, demonstrating that even a promising strain does not produce uniform results across trials. | ||
[https://pubmed.ncbi.nlm.nih.gov/22912552/ | Philippe Ducrotté et al. | World Journal of Gastroenterology | 2012] | |||
[https:// | A randomized double-blind placebo-controlled trial evaluates Lactobacillus plantarum 299v, also designated DSM 9843, in adults with IBS. Four weeks of treatment improved overall symptoms, with particularly notable reductions in abdominal pain and bloating. | ||
[https://pubmed.ncbi.nlm.nih.gov/11711768/ | K. Niedzielin et al. | European Journal of Gastroenterology & Hepatology | 2001] | |||
[https:// | An early double-blind randomized controlled trial evaluates Lactobacillus plantarum 299v in people with IBS. Participants receiving 299v reported substantially greater global improvement in IBS symptoms than those receiving placebo. | ||
===== | ===Bacillus coagulans Unique IS2 — IBS and Functional Constipation=== | ||
[https://pubmed.ncbi.nlm.nih.gov/37686889/ | P. Xie et al. | Nutrients | 2023] | |||
[https:// | A strain-level network meta-analysis compares individual probiotics for IBS outcomes. Bacillus coagulans Unique IS2 ranked among the strongest-performing interventions for abdominal pain. | ||
[https://pubmed.ncbi.nlm.nih.gov/30911991/ | R. S. Madempudi et al. | Beneficial Microbes | 2020] | |||
[https:// | A randomized double-blind placebo-controlled study evaluates Bacillus coagulans Unique IS2 in adults with functional constipation. Supplementation increased spontaneous bowel movements and reduced several constipation-related symptoms compared with placebo. | ||
[https://pubmed.ncbi.nlm.nih.gov/31434935/ | R. S. Madempudi et al. | Scientific Reports | 2019] | |||
[https:// | A randomized double-blind placebo-controlled trial evaluates Bacillus coagulans Unique IS2 in adults with IBS. The strain produced significant improvements in abdominal pain and several other IBS symptoms compared with placebo. | ||
[https://pubmed.ncbi.nlm.nih.gov/29695183/ | M. Ratna Sudha et al. | Beneficial Microbes | 2018] | |||
[https:// | A randomized placebo-controlled trial evaluates Bacillus coagulans Unique IS2 in children ages four through twelve with IBS. The strain significantly reduced pain intensity and improved abdominal discomfort, bloating, stool consistency, urgency, incomplete evacuation, and overall bowel satisfaction. | ||
===== | ===Bacillus coagulans MTCC 5856 — Diarrhea-Predominant IBS=== | ||
[https://pubmed.ncbi.nlm.nih.gov/26922379/ | Muhammed Majeed et al. | Nutrition Journal | 2016] | |||
[https:// | A randomized double-blind placebo-controlled trial evaluates Bacillus coagulans MTCC 5856 in adults with diarrhea-predominant IBS. Ninety days of supplementation improved several IBS symptoms and quality-of-life measures compared with placebo. | ||
=== | ===Bifidobacterium animalis subsp. lactis HN019 — Constipation and Gut Transit=== | ||
[https://pubmed.ncbi.nlm.nih.gov/39356506/ | J. Cheng et al. | American Journal of Gastroenterology | 2024] | |||
[https:// | An eight-week randomized trial further evaluates Bifidobacterium animalis subsp. lactis HN019 in adults with constipation, adding to the clinical literature concerning this strain and bowel-movement frequency. | ||
[https://pubmed.ncbi.nlm.nih.gov/29227175/ | A. Ibarra et al. | Gut Microbes | 2018] | |||
[https:// | A randomized controlled trial evaluates Bifidobacterium animalis subsp. lactis HN019 in 228 adults with functional constipation. Two daily doses were studied for effects on complete spontaneous bowel movements, stool consistency, straining, and related symptoms. | ||
[https://pubmed.ncbi.nlm.nih.gov/21663486/ | P. A. Waller et al. | Scandinavian Journal of Gastroenterology | 2011] | |||
[https:// | A randomized clinical trial examines different doses of Bifidobacterium lactis HN019. Supplementation shortened whole-gut transit time and improved the frequency of gastrointestinal symptoms. | ||
=== | ===Bifidobacterium animalis subsp. lactis BB-12 — Infantile Colic=== | ||
[https://pubmed.ncbi.nlm.nih.gov/34550055/ | K. Chen et al. | Nutrients | 2021] | |||
[https:// | A clinical study evaluates Bifidobacterium animalis subsp. lactis BB-12 in infants diagnosed with colic. BB-12 supplementation reduced crying and fussing. | ||
===== | ===Lactobacillus acidophilus NCFM — IBS and Functional Bowel Symptoms=== | ||
[https://pubmed.ncbi.nlm.nih.gov/28082816/ | Anna Lyra et al. | World Journal of Gastroenterology | 2016] | |||
[https:// | A randomized placebo-controlled study evaluates Lactobacillus acidophilus NCFM in people with irritable bowel syndrome. NCFM supplementation was associated with improvements in IBS symptom severity in some participants. | ||
[https://pubmed.ncbi.nlm.nih.gov/24853043/ | T. Ringel-Kulka et al. | Alimentary Pharmacology & Therapeutics | 2014] | |||
[https:// | A randomized clinical study examines Lactobacillus acidophilus NCFM in people with functional abdominal pain. | ||
[https://pubmed.ncbi.nlm.nih.gov/21436726/ | T. Ringel-Kulka et al. | Journal of Clinical Gastroenterology | 2011] | |||
[https:// | A randomized controlled trial evaluates Lactobacillus acidophilus NCFM together with Bifidobacterium lactis Bi-07 in patients with functional bowel disorders. The probiotic treatment significantly improved bloating compared with placebo. | ||
===== | ===Lactobacillus casei Shirota — Constipation=== | ||
[https://pubmed.ncbi.nlm.nih.gov/36372047/ | A. van der Schoot et al. | Clinical Nutrition | 2022] | |||
[https:// | A systematic review and meta-analysis examines individual probiotics and synbiotics for chronic constipation in adults. Lactobacillus casei Shirota was among the specifically identified strains studied. | ||
[https://pubmed.ncbi.nlm.nih.gov/36570175/ | M. M. Araújo et al. | Nutrients | 2022] | |||
[https:// | A systematic review identifies Lactobacillus casei Shirota as one of the better-studied individual strains for chronic constipation. | ||
[https://pubmed.ncbi.nlm.nih.gov/20039451/ | Anna Chmielewska and Hania Szajewska | World Journal of Gastroenterology | 2010] | |||
[https:// | A systematic review reports favorable adult evidence for Lactobacillus casei Shirota, particularly for defecation frequency and stool consistency. | ||
===== | ===Lactobacillus crispatus CTV-05 — Recurrent Urinary Tract Infection=== | ||
[https://pubmed.ncbi.nlm.nih.gov/16827601/ | Matthew E. Falagas et al. | Drugs | 2006] | |||
[ | A systematic review identifies Lactobacillus crispatus CTV-05 among strains showing promising preventive effects for recurrent urinary tract infection in women. | ||
=== | ===Lacticaseibacillus paracasei CNCM I-1518 — Respiratory and Gastrointestinal Infections=== | ||
[https://pubmed.ncbi.nlm.nih.gov/34200435/ | M. Strauss et al. | Frontiers in Nutrition | 2021] | |||
[https:// | A systematic review evaluates individual probiotic strains for prevention of acute respiratory tract infections. Lacticaseibacillus paracasei CNCM I-1518 is among the strains supported by randomized placebo-controlled studies. | ||
[https://pubmed.ncbi.nlm.nih.gov/33182682/ | Theresa Poon et al. | Nutrients | 2020] | |||
[https:// | A systematic review and meta-analysis of nine randomized trials evaluates a fermented dairy preparation containing Lacticaseibacillus paracasei CNCM I-1518 together with yogurt cultures. | ||
===Probiotics and Parkinson’s Disease=== | |||
[https://pubmed.ncbi.nlm.nih.gov/41078360/ | X. Gu et al. | PubMed | 2025] | |||
[https:// | A systematic review and meta-analysis evaluates therapies targeting the intestinal microbiota in Parkinson’s disease. | ||
[https://pubmed.ncbi.nlm.nih.gov/41126787/ | V. Leta et al. | PubMed | 2025] | |||
[https:// | A clinical study evaluates a four-strain probiotic in people with Parkinson’s disease. | ||
[https://pubmed.ncbi.nlm.nih.gov/39228448/ | E. S. Atak et al. | PubMed / Basic and Clinical Neuroscience | 2024] | |||
[https:// | A systematic review of randomized controlled trials evaluates potential therapeutic targets of probiotics in Parkinson’s disease. | ||
===== | [https://pubmed.ncbi.nlm.nih.gov/38705493/ | X. Jin et al. | PubMed | 2024] | ||
[https:// | A systematic review and meta-analysis evaluates probiotic supplements in Parkinson’s disease. | ||
Probiotics | |||
[https://pubmed.ncbi.nlm.nih.gov/38878554/ | A. M. Mincic et al. | PubMed | 2024] | |||
A review evaluates manipulation of the intestinal microbiome in neurodegenerative disorders including Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, and amyotrophic lateral sclerosis. | |||
[https://pubmed.ncbi.nlm.nih.gov/38474254/ | A. I. Beltrán-Velasco et al. | PubMed | 2024] | |||
A systematic review examines Lactiplantibacillus plantarum as a potential intervention for neurodegenerative diseases. | |||
===Probiotics, Alzheimer’s Disease, and Cognitive Function=== | |||
[https://pubmed.ncbi.nlm.nih.gov/40034358/ | S. Tripathi et al. | PubMed | 2024] | |||
A systematic review and meta-analysis evaluates individual cognitive domains in people with mild cognitive impairment and Alzheimer’s disease. | |||
[https://pubmed.ncbi.nlm.nih.gov/39678681/ | F. Zhu et al. | PubMed | 2024] | |||
A systematic analysis examines probiotic interventions across neurodegenerative diseases. | |||
[https://pubmed.ncbi.nlm.nih.gov/38641508/ | R. Mo et al. | PubMed | 2024] | |||
A meta-analysis investigates probiotic supplementation in people with Alzheimer’s disease and mild cognitive impairment. | |||
[https://pubmed.ncbi.nlm.nih.gov/27891089/ | E. Akbari et al. | Frontiers in Aging Neuroscience | 2016] | |||
A randomized double-blind controlled trial investigates probiotic supplementation in people with Alzheimer’s disease. | |||
===Probiotics and Polycystic Ovary Syndrome=== | |||
[https://pubmed.ncbi.nlm.nih.gov/39599701/ | D. M. Guevara et al. | PubMed | 2024] | |||
A systematic review of randomized clinical trials evaluates probiotics, prebiotics, and synbiotics in women with polycystic ovary syndrome. | |||
[https://pubmed.ncbi.nlm.nih.gov/38421576/ | S. Salehi et al. | PubMed | 2024] | |||
A review examines alterations of the intestinal microbiota in polycystic ovary syndrome. | |||
[https://pubmed.ncbi.nlm.nih.gov/34970669/ | S. Alesi et al. | PubMed | 2022] | |||
A comprehensive review examines nutritional supplements and complementary therapies in PCOS. | |||
[https://pubmed.ncbi.nlm.nih.gov/29532416/ | M. Samimi et al. | PubMed | 2019] | |||
A randomized controlled trial evaluates synbiotic supplementation in women with PCOS. | |||
[https://pubmed.ncbi.nlm.nih.gov/29664663/ | M. Karamali et al. | PubMed | 2018] | |||
A randomized trial evaluates probiotic supplementation and hormonal profiles in women with PCOS. | |||
[https://pubmed.ncbi.nlm.nih.gov/28142296/ | S. Ahmadi et al. | PubMed | 2017] | |||
A clinical trial examines probiotic supplementation in women with PCOS. | |||
===Probiotics and Liver Cirrhosis=== | |||
[https://pubmed.ncbi.nlm.nih.gov/39267392/ | Y. L. Zhou et al. | PubMed | 2024] | |||
A meta-analysis evaluates probiotics for minimal hepatic encephalopathy. | |||
[https://pubmed.ncbi.nlm.nih.gov/39174901/ | Y. Pan et al. | PubMed | 2024] | |||
A systematic analysis compares probiotics, prebiotics, and synbiotics for liver-related outcomes. | |||
[https://pubmed.ncbi.nlm.nih.gov/38701917/ | Researchers | PubMed | 2024] | |||
A systematic review evaluates probiotics in cirrhosis complicated by portal hypertension. | |||
[https://pubmed.ncbi.nlm.nih.gov/38618195/ | Xing Yang et al. | Frontiers in Medicine | 2024] | |||
A systematic review and meta-analysis of 30 randomized studies evaluates probiotics in liver cirrhosis. | |||
[https://pubmed.ncbi.nlm.nih.gov/37502435/ | I. D. N. Wibawa et al. | PubMed | 2023] | |||
A systematic review and meta-analysis examines probiotics for minimal hepatic encephalopathy. | |||
[https://pubmed.ncbi.nlm.nih.gov/36595801/ | L. Huang et al. | PubMed | 2022] | |||
A review examines alterations of the intestinal microbiome in cirrhosis and the effects of probiotic supplementation. | |||
[https://pubmed.ncbi.nlm.nih.gov/24246768/ | M. K. Lunia et al. | PubMed | 2014] | |||
A randomized controlled trial investigates probiotics for preventing hepatic encephalopathy in patients with cirrhosis. | |||
===Probiotics and Acne=== | |||
[https://pubmed.ncbi.nlm.nih.gov/40832719/ | H. W. Lin et al. | PubMed | 2025] | |||
A systematic review and meta-analysis evaluates oral probiotics for acne vulgaris. | |||
[https://pubmed.ncbi.nlm.nih.gov/39810881/ | I. A. M. P. Sutema et al. | PubMed | 2025] | |||
A systematic review examines oral and topical probiotic treatments for acne and skin health. | |||
[https://pubmed.ncbi.nlm.nih.gov/39269130/ | A. Podwojniak et al. | PubMed | 2025] | |||
A systematic review examines acne and the cutaneous microbiome. | |||
[https://pubmed.ncbi.nlm.nih.gov/38472474/ | A. Boby et al. | Archives of Dermatological Research | 2024] | |||
A systematic review assesses probiotics for treating acne vulgaris. | |||
[https://pubmed.ncbi.nlm.nih.gov/32266790/ | A. Goodarzi et al. | PubMed | 2020] | |||
A review explores probiotics as adjunctive therapy for acne vulgaris. | |||
===Probiotics and Psoriasis=== | |||
[https://pubmed.ncbi.nlm.nih.gov/40333159/ | Y. Gao et al. | PubMed | 2025] | |||
A review synthesizes evidence concerning intestinal dysbiosis in psoriasis and evaluates probiotics and other microbiome-directed treatments. | |||
[https://pubmed.ncbi.nlm.nih.gov/39328313/ | Y. Zhu et al. | PubMed | 2024] | |||
A systematic review and meta-analysis evaluates probiotics as adjunctive therapy for psoriasis. | |||
[https://pubmed.ncbi.nlm.nih.gov/38551321/ | K. Wei et al. | PubMed | 2024] | |||
A systematic review and meta-analysis evaluates probiotic supplementation for psoriasis. | |||
[https://pubmed.ncbi.nlm.nih.gov/34938815/ | L. Zeng et al. | PubMed | 2021] | |||
A systematic review examines the effectiveness and safety of probiotic supplementation for psoriasis. | |||
===Probiotics and Allergic Rhinitis=== | |||
[https://pubmed.ncbi.nlm.nih.gov/39421038/ | X. Luo et al. | PubMed | 2024] | |||
A systematic review and meta-analysis evaluates probiotics for preventing and treating allergic rhinitis in children. | |||
[https://pubmed.ncbi.nlm.nih.gov/35663980/ | C. Luo et al. | PubMed | 2022] | |||
A systematic review and meta-analysis examines the effectiveness and safety of probiotics for allergic rhinitis. | |||
[https://pubmed.ncbi.nlm.nih.gov/35527653/ | S. Yan et al. | PubMed | 2022] | |||
A systematic review and meta-analysis evaluates probiotics for allergic rhinitis. | |||
[https://pubmed.ncbi.nlm.nih.gov/35099301/ | K. Farahmandi et al. | PubMed | 2022] | |||
A strain-specific systematic review evaluates probiotics for allergic rhinitis. | |||
[https://pubmed.ncbi.nlm.nih.gov/25899251/ | A. E. Zajac et al. | PubMed | 2015] | |||
A systematic review and meta-analysis evaluates probiotics in allergic rhinitis. | |||
===Probiotics and Pediatric Asthma=== | |||
[https://pubmed.ncbi.nlm.nih.gov/40352259/ | D. Fan et al. | PubMed | 2025] | |||
A systematic review evaluates probiotics, prebiotics, synbiotics, and postbiotics for pediatric asthma. | |||
===Probiotics and COVID-19=== | |||
[https://pubmed.ncbi.nlm.nih.gov/41004357/ | C. H. H. Chau et al. | PubMed | 2025] | |||
A systematic review and meta-analysis evaluates probiotics for prevention and treatment of COVID-19. | |||
[https://pubmed.ncbi.nlm.nih.gov/39849406/ | N. T. Iqbal et al. | PubMed | 2025] | |||
A review examines persistent intestinal dysbiosis associated with COVID-19 and post-COVID conditions. | |||
[https://pubmed.ncbi.nlm.nih.gov/39614066/ | T. Amrouche et al. | PubMed | 2025] | |||
A review examines probiotic and prebiotic interventions in respiratory and viral infections. | |||
===Probiotics and Multiple Sclerosis=== | |||
[https://pubmed.ncbi.nlm.nih.gov/40273120/ | Z. Zangeneh et al. | PubMed | 2025] | |||
A systematic review and meta-analysis examines probiotics in multiple sclerosis using both clinical and experimental studies. | |||
===Probiotics and Systemic Lupus Erythematosus=== | |||
[https://pubmed.ncbi.nlm.nih.gov/40216660/ | L. Jin et al. | PubMed | 2025] | |||
A review explores intestinal microbiota alterations in systemic lupus erythematosus. | |||
[https://pubmed.ncbi.nlm.nih.gov/38806966/ | Rachael Chaeh-Wen Goh et al. | PubMed | 2025] | |||
A systematic review evaluates probiotic therapy in experimental models of systemic lupus erythematosus. | |||
===Probiotics, Osteoporosis, and Bone Health=== | |||
[https://pubmed.ncbi.nlm.nih.gov/40716641/ | J. N. Harini et al. | PubMed | 2025] | |||
A systematic review evaluates probiotic supplementation and bone mineral density. | |||
[https://pubmed.ncbi.nlm.nih.gov/39643654/ | A. Ticinesi et al. | PubMed | 2025] | |||
A review examines the relationship between intestinal microbiota and bone health. | |||
[https://pubmed.ncbi.nlm.nih.gov/39553313/ | F. Wang et al. | PubMed | 2024] | |||
A systematic review and meta-analysis examines probiotic supplementation and bone health in postmenopausal women. | |||
===Probiotics and Celiac Disease=== | |||
[https://pubmed.ncbi.nlm.nih.gov/40887812/ | T. C. Scherer et al. | PubMed | 2025] | |||
A review examines mechanisms through which probiotic bifidobacteria may affect responses to gluten-derived peptides. | |||
[https://pubmed.ncbi.nlm.nih.gov/40771499/ | F. Valitutti et al. | PubMed | 2025] | |||
A review examines intestinal microbiota in celiac disease and the possibility of personalized microbiome-directed treatment. | |||
===Probiotics and Menopausal Health=== | |||
[https://pubmed.ncbi.nlm.nih.gov/40639456/ | R. A. F. Andrews et al. | PubMed | 2025] | |||
A systematic review and meta-analysis evaluates probiotics in peri- and postmenopausal women. | |||
===Probiotics and Irritable Bowel Syndrome=== | |||
[https://pubmed.ncbi.nlm.nih.gov/39830577/ | B. A. Almabruk et al. | PubMed | 2024] | |||
A systematic review and meta-analysis evaluates probiotics for irritable bowel syndrome, including abdominal symptoms and quality of life. | |||
[https://pubmed.ncbi.nlm.nih.gov/39575029/ | A. Manandhar et al. | PubMed | 2024] | |||
A systematic review examines probiotic treatment in adults with irritable bowel syndrome and inflammatory bowel disease. | |||
[https://pubmed.ncbi.nlm.nih.gov/38999862/ | Y. Wu et al. | PubMed | 2024] | |||
A network meta-analysis compares probiotics, prebiotics, synbiotics, and fecal microbiota transplantation for IBS. | |||
[https://pubmed.ncbi.nlm.nih.gov/38479936/ | R. Yang et al. | PubMed | 2024] | |||
A meta-analysis of 20 studies involving more than 3,000 patients evaluates the efficacy and safety of probiotics in IBS. | |||
[https://pubmed.ncbi.nlm.nih.gov/37541528/ | V. C. Goodoory et al. | PubMed | 2023] | |||
A large systematic review and meta-analysis evaluates individual probiotic strains and combinations for IBS. | |||
[https://pubmed.ncbi.nlm.nih.gov/32317962/ | B. Li et al. | PubMed | 2020] | |||
A systematic review and meta-analysis assesses the efficacy and safety of probiotics for IBS. | |||
[https://pubmed.ncbi.nlm.nih.gov/31898645/ | J. R. Sun et al. | PubMed | 2020] | |||
A meta-analysis examines probiotic combinations, species, and strains used for IBS. | |||
===Probiotics and Recurrent Urinary Tract Infections=== | |||
[https://pubmed.ncbi.nlm.nih.gov/39095666/ | Z. Han et al. | PubMed | 2025] | |||
A network meta-analysis evaluates non-antibiotic strategies for preventing urinary tract infections. | |||
[https://pubmed.ncbi.nlm.nih.gov/38930419/ | M. Daniel et al. | PubMed | 2024] | |||
A double-blind randomized controlled trial evaluates Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 for preventing recurrent urinary tract infections in children. | |||
[https://pubmed.ncbi.nlm.nih.gov/38773400/ | E. J. Nelwan et al. | PubMed | 2024] | |||
A meta-analysis evaluates probiotics as adjunctive treatments for several infectious diseases. | |||
[https://pubmed.ncbi.nlm.nih.gov/38084984/ | V. Gupta et al. | PubMed | 2024] | |||
A randomized controlled study examines oral and vaginal probiotic prophylaxis for recurrent urinary tract infections in women. | |||
[https://pubmed.ncbi.nlm.nih.gov/35156175/ | F. J. New et al. | PubMed | 2022] | |||
A systematic review evaluates probiotics for recurrent urinary tract infections. | |||
[https://pubmed.ncbi.nlm.nih.gov/30487041/ | T. Akgül and B. Karakan | PubMed | 2018] | |||
A review examines the relationship between vaginal and urinary microbiota and recurrent urinary tract infection. | |||
===Probiotics and Migraine=== | |||
[https://pubmed.ncbi.nlm.nih.gov/41070562/ | O. Grodzka et al. | PubMed | 2025] | |||
A clinical review examines the gut microbiota, gut-brain axis, and migraine. | |||
[https://pubmed.ncbi.nlm.nih.gov/39404918/ | M. K. Talandashti et al. | PubMed | 2025] | |||
A systematic review and meta-analysis compares several dietary supplements used for migraine prevention. | |||
[https://pubmed.ncbi.nlm.nih.gov/39394141/ | S. A. Tirani et al. | PubMed | 2024] | |||
A randomized clinical trial examines combined probiotic and vitamin D supplementation in people with migraine. | |||
[https://pubmed.ncbi.nlm.nih.gov/38617394/ | H. Bazmamoum et al. | PubMed | 2024] | |||
A clinical study evaluates probiotics as an adjunct to standard migraine treatment in children. | |||
===Probiotics and Rheumatoid Arthritis=== | |||
[https://pubmed.ncbi.nlm.nih.gov/41030267/ | K. Van den Bruel et al. | PubMed | 2025] | |||
A systematic review examines diets, dietary supplements, and probiotics in rheumatoid arthritis and related inflammatory disorders. | |||
[https://pubmed.ncbi.nlm.nih.gov/40054644/ | X. E. Cheng et al. | PubMed | 2025] | |||
A systematic review evaluates nutritional supplements and dietary interventions for rheumatoid arthritis. | |||
[https://pubmed.ncbi.nlm.nih.gov/38873605/ | W. Li et al. | PubMed | 2024] | |||
An overview of systematic reviews and meta-analyses assesses the quality of evidence supporting probiotics for rheumatoid arthritis. | |||
[https://pubmed.ncbi.nlm.nih.gov/38510244/ | Y. Yang et al. | PubMed | 2024] | |||
A review explores the intestinal microbiome in rheumatoid arthritis and discusses probiotic treatment. | |||
[https://pubmed.ncbi.nlm.nih.gov/37294082/ | H. C. Blenkinsopp et al. | PubMed | 2024] | |||
A review examines intestinal permeability, microbial imbalance, and rheumatoid arthritis. | |||
[https://pubmed.ncbi.nlm.nih.gov/32771911/ | J. R. Lowe et al. | PubMed | 2020] | |||
A systematic review evaluates formulation-specific probiotic effects in inflammatory arthritis. | |||
===Probiotics and Chronic Kidney Disease=== | |||
[https://pubmed.ncbi.nlm.nih.gov/40573072/ | S. Wakino et al. | PubMed | 2025] | |||
A review examines the kidney-gut axis in chronic kidney disease and microbiome-directed treatment strategies. | |||
[https://pubmed.ncbi.nlm.nih.gov/39795549/ | K. Tsuji et al. | PubMed | 2024] | |||
A review examines the gut-kidney axis and how intestinal dysbiosis may influence chronic kidney disease. | |||
[https://pubmed.ncbi.nlm.nih.gov/39758318/ | J. Ruszkowski et al. | PubMed | 2024] | |||
A systematic review and meta-analysis evaluates probiotic and synbiotic supplementation in chronic kidney disease. | |||
[https://pubmed.ncbi.nlm.nih.gov/39723354/ | N. Stepanova et al. | PubMed | 2024] | |||
A review focuses on probiotic interventions among people receiving peritoneal dialysis. | |||
[https://pubmed.ncbi.nlm.nih.gov/39166132/ | C. Liu et al. | PubMed | 2024] | |||
A systematic review and meta-analysis assesses probiotics and synbiotics in patients with chronic kidney disease. | |||
[https://pubmed.ncbi.nlm.nih.gov/24231662/ | A. Ramezani and D. S. Raj | PubMed | 2014] | |||
A foundational review explores alterations of the intestinal microbiome in chronic kidney disease. | |||
===Probiotics and Periodontal Disease=== | |||
[https://pubmed.ncbi.nlm.nih.gov/39508204/ | C. Mendonça et al. | PubMed | 2025] | |||
An umbrella review examines 30 systematic reviews concerning probiotics for periodontal and peri-implant diseases. | |||
[https://pubmed.ncbi.nlm.nih.gov/39927018/ | N. S. Abdul et al. | PubMed | 2024] | |||
A systematic review investigates probiotics for prevention and treatment of periodontal disease. | |||
[https://pubmed.ncbi.nlm.nih.gov/39609381/ | H. Sharma et al. | Indian Journal of Dental Research | 2024] | |||
An overview of 22 systematic reviews and meta-analyses examines probiotic supplementation for periodontal disease. | |||
[https://pubmed.ncbi.nlm.nih.gov/39513100/ | H. Doucette et al. | PubMed | 2024] | |||
A review examines how prebiotics and probiotics may affect the oral microbiome. | |||
[https://pubmed.ncbi.nlm.nih.gov/39407177/ | Carlota Duarte de Mendonça et al. | BMC Oral Health | 2024] | |||
A systematic review and network meta-analysis evaluates probiotics added to professional mechanical plaque removal for periodontitis. | |||
[https://pubmed.ncbi.nlm.nih.gov/38497853/ | J. Ram et al. | PubMed | 2024] | |||
A systematic review examines Lactobacillus reuteri as an adjunct to scaling and root planing in chronic periodontitis. | |||
[https://pubmed.ncbi.nlm.nih.gov/37964394/ | L. Puzhankara et al. | Oral Diseases | 2024] | |||
A systematic review compares probiotics with antibiotics for managing gingivitis and periodontitis. | |||
===Probiotics, Autoimmune Disease, and Inflammation=== | |||
[https://pubmed.ncbi.nlm.nih.gov/41978157/ | Researchers | PubMed | 2026] | |||
A systematic review and meta-analysis examines oral probiotic and synbiotic supplementation across autoimmune diseases. | |||
[https://pubmed.ncbi.nlm.nih.gov/38765017/ | X. Wang et al. | PubMed | 2024] | |||
A review examines the emerging relationship between intestinal microbiota and autoimmune disease. | |||
[https://pubmed.ncbi.nlm.nih.gov/38475833/ | L. Zeng et al. | PubMed | 2024] | |||
A systematic review and meta-analysis evaluates gut microbiota-based therapies across autoimmune diseases. | |||
===Probiotics and Kidney Stones=== | |||
[https://pubmed.ncbi.nlm.nih.gov/38682062/ | H. Taheri et al. | PubMed | 2024] | |||
A review examines probiotics and herbal interventions for kidney stones and nephrolithiasis. | |||
===Probiotics and Atopic Dermatitis=== | |||
[https://pubmed.ncbi.nlm.nih.gov/41762435/ | Researchers | PubMed / Springer | 2026] | |||
An umbrella review evaluates systematic reviews and meta-analyses examining probiotics for atopic dermatitis and related allergic conditions in infants and children. | |||
[https://pubmed.ncbi.nlm.nih.gov/41675035/ | Researchers | Journal of Allergy and Clinical Immunology: Global | 2026] | |||
A systematic review and meta-analysis examines randomized trials of probiotics for eczema and atopic dermatitis in children and adolescents. | |||
[https://pubmed.ncbi.nlm.nih.gov/40740395/ | Researchers | Indian Journal of Dermatology | 2025] | |||
A systematic review and meta-analysis examines probiotic supplementation for adults with atopic dermatitis. | |||
[https://pubmed.ncbi.nlm.nih.gov/37706436/ | Researchers | PubMed | 2023] | |||
A systematic review and meta-analysis evaluates probiotic supplementation in adults with atopic dermatitis. | |||
[https://pubmed.ncbi.nlm.nih.gov/32524647/ | Researchers | Pediatric Allergy and Immunology | 2020] | |||
A network meta-analysis compares different probiotic strains used to treat pediatric atopic dermatitis. | |||
===Probiotics and Helicobacter pylori=== | |||
[https://pubmed.ncbi.nlm.nih.gov/41581709/ | Researchers | Microbial Pathogenesis | 2026] | |||
A meta-analysis of 28 randomized controlled trials evaluates probiotic monotherapy for reducing Helicobacter pylori colonization without antibiotics. | |||
===Probiotics and Oral Health=== | |||
[https://pubmed.ncbi.nlm.nih.gov/41969406/ | Researchers | Frontiers in Oral Health | 2026] | |||
An umbrella review of meta-analyses examines probiotic interventions for dental and oral health. | |||
[https://pubmed.ncbi.nlm.nih.gov/41331162/ | Researchers | PubMed | 2025] | |||
A systematic review evaluates randomized clinical trials investigating probiotics for enamel demineralization and cariogenic bacteria. | |||
[https://pubmed.ncbi.nlm.nih.gov/37765121/ | Researchers | PubMed | 2023] | |||
A systematic review investigates probiotics and oral health, including dental caries, periodontal disease, halitosis, mucositis and peri-implant conditions. | |||
===Probiotics and Obesity, Cholesterol, and Metabolic Health=== | |||
[https://pubmed.ncbi.nlm.nih.gov/42130343/ | Researchers | Obesity Reviews | 2026] | |||
A systematic review and meta-analysis examines probiotic and synbiotic supplementation and lipid levels among people with overweight and obesity. | |||
[https://pubmed.ncbi.nlm.nih.gov/39298907/ | Researchers | Diabetes & Metabolic Syndrome | 2024] | |||
A systematic review and meta-analysis evaluates probiotics, prebiotics, synbiotics and other microbiome-modifying therapies for metabolic syndrome. | |||
[https://pubmed.ncbi.nlm.nih.gov/34358838/ | Researchers | Clinical Nutrition | 2021] | |||
A meta-analysis of 26 randomized controlled trials involving 1,720 participants evaluates probiotics for people with overweight or obesity. | |||
[https://pubmed.ncbi.nlm.nih.gov/34237694/ | Researchers | PubMed | 2021] | |||
A systematic review and meta-analysis examines probiotic and synbiotic supplementation in adults with metabolic syndrome. | |||
[https://pubmed.ncbi.nlm.nih.gov/32860083/ | Researchers | Current Atherosclerosis Reports | 2020] | |||
A systematic review and meta-analysis examines probiotics and cardiovascular disease risk factors. | |||
[https://pubmed.ncbi.nlm.nih.gov/31118956/ | Researchers | PubMed | 2019] | |||
A systematic review and meta-analysis examines probiotics for overweight and obesity. | |||
===Probiotics and Fatty Liver Disease=== | |||
[https://pubmed.ncbi.nlm.nih.gov/38643738/ | Researchers | PubMed | 2024] | |||
A network meta-analysis compares different probiotic combinations for nonalcoholic fatty liver disease. | |||
[https://pubmed.ncbi.nlm.nih.gov/34877910/ | Researchers | Expert Review of Gastroenterology & Hepatology | 2022] | |||
A systematic review and meta-analysis evaluates randomized controlled trials of probiotics for nonalcoholic fatty liver disease. | |||
[https://pubmed.ncbi.nlm.nih.gov/24187469/ | Researchers | PubMed | 2013] | |||
An early meta-analysis examines probiotic treatment for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. | |||
===Probiotics and Constipation=== | |||
[https://pubmed.ncbi.nlm.nih.gov/35745212/ | Researchers | Nutrients | 2022] | |||
A systematic review and meta-analysis examines probiotics for constipation-predominant irritable bowel syndrome. | |||
[https://pubmed.ncbi.nlm.nih.gov/29118557/ | Researchers | PubMed | 2017] | |||
A systematic review and meta-analysis examines probiotic products for constipation in adults. | |||
[https://pubmed.ncbi.nlm.nih.gov/25099542/ | Researchers | American Journal of Clinical Nutrition | 2014] | |||
A systematic review and meta-analysis evaluates probiotics for functional constipation in adults. | |||
===Probiotics and Bacterial Vaginosis=== | |||
[https://pubmed.ncbi.nlm.nih.gov/35049024/ | Researchers | PubMed | 2022] | |||
A systematic review and meta-analysis evaluates probiotics for bacterial vaginosis. | |||
[https://pubmed.ncbi.nlm.nih.gov/31562865/ | Researchers | European Journal of Pharmacology | 2019] | |||
A systematic review and meta-analysis of 13 randomized clinical trials evaluates probiotics alone and in combination with antibiotics for bacterial vaginosis. | |||
Revision as of 03:38, 15 August 2026
Lacticaseibacillus rhamnosus GG (LGG) — Antibiotic-Associated Diarrhea
| Researchers | Journal of Clinical Gastroenterology | 2018
A network meta-analysis involving more than 9,000 participants compares different probiotics for prevention of antibiotic-associated diarrhea. Lactobacillus rhamnosus GG had the highest probability of ranking among the most effective and best-tolerated probiotic interventions.
| V. Agamennone et al. | European Journal of Clinical Pharmacology | 2018
A strain-specific analysis of probiotic preparations used to prevent antibiotic-associated diarrhea identifies seven effective formulations. Lactobacillus rhamnosus GG produced one of the strongest effects, with substantially less antibiotic-associated diarrhea than placebo.
| C. Mantegazza et al. | Nutrients | 2018
A clinical review of probiotics for pediatric antibiotic-associated diarrhea finds the strongest strain-specific evidence for Lactobacillus rhamnosus GG and Saccharomyces boulardii. The authors emphasize that results obtained with these strains should not be generalized to other probiotics.
| Hania Szajewska et al. | Journal of Pediatric Gastroenterology and Nutrition | 2016
Evidence-based recommendations from the European Society for Pediatric Gastroenterology, Hepatology and Nutrition identify Lactobacillus rhamnosus GG as one of the probiotic strains with sufficient evidence to recommend for preventing antibiotic-associated diarrhea in children.
| Hania Szajewska and Marek Kołodziej | Alimentary Pharmacology & Therapeutics | 2015
A strain-specific systematic review and meta-analysis evaluates Lactobacillus rhamnosus GG, commonly abbreviated LGG, for prevention of antibiotic-associated diarrhea. LGG significantly reduced antibiotic-associated diarrhea in children and adults, although the certainty of evidence was rated moderate to low. This is one of the better-supported strain-specific uses of probiotics.
| Lynne V. McFarland | Annals of Nutrition and Metabolism | 2015
A strain-specific review of probiotics for pediatric antibiotic-associated diarrhea finds significant preventive effects for Lactobacillus rhamnosus GG as well as Saccharomyces boulardii.
| Jason Hawrelak et al. | Digestive Diseases and Sciences | 2005
A systematic review evaluates Lactobacillus rhamnosus GG specifically for preventing antibiotic-associated diarrhea. Four of six qualifying clinical trials reported a significant reduction in diarrhea risk, while another showed fewer days with antibiotic-associated diarrhea.
Saccharomyces boulardii — Antibiotic-Associated Diarrhea
| M. Storr et al. | Medizinische Klinik | 2021
A clinical review emphasizes that prevention of antibiotic-associated diarrhea is strain-specific. The authors identify Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG as evidence-based options rather than recommending probiotics as a general category.
| Hania Szajewska and Marek Kołodziej | Alimentary Pharmacology & Therapeutics | 2015
A systematic review and meta-analysis evaluates the probiotic yeast Saccharomyces boulardii specifically for antibiotic-associated diarrhea. Supplementation significantly reduced the risk of antibiotic-associated diarrhea among both children and adults.
| Lynne V. McFarland | World Journal of Gastroenterology | 2010
A large systematic review examines Saccharomyces boulardii across multiple gastrointestinal disorders. Twenty-seven randomized controlled studies involving more than 5,000 participants were analyzed, with particularly strong evidence for prevention of antibiotic-associated diarrhea.
| Lynne V. McFarland | American Journal of Gastroenterology | 2006
A meta-analysis evaluates probiotics for antibiotic-associated diarrhea and Clostridium difficile disease. Saccharomyces boulardii and Lactobacillus rhamnosus GG were among the probiotic interventions significantly associated with prevention of antibiotic-associated diarrhea.
| Hania Szajewska and Jacek Mrukowicz | Alimentary Pharmacology & Therapeutics | 2005
A strain-focused meta-analysis of randomized controlled trials finds Saccharomyces boulardii moderately effective for preventing antibiotic-associated diarrhea in children and adults.
| M. Kotowska et al. | Alimentary Pharmacology & Therapeutics | 2005
A randomized placebo-controlled trial evaluates Saccharomyces boulardii for preventing antibiotic-associated diarrhea in children. Children receiving the probiotic developed substantially less antibiotic-associated diarrhea than those receiving placebo.
Limosilactobacillus reuteri DSM 17938 — Infantile Colic
| Valerie Sung et al. | Pediatrics | 2018
An individual-participant-data meta-analysis evaluates Lactobacillus reuteri DSM 17938 specifically for infantile colic. DSM 17938 reduced crying duration and increased treatment response among breastfed infants. Evidence was insufficient to reach the same conclusion for formula-fed infants.
| P. Gutiérrez-Castrellón et al. | Medicine | 2017
A network meta-analysis compares treatments for infantile colic. Lactobacillus reuteri DSM 17938 was among the interventions associated with meaningful reductions in infant colic symptoms.
| K. Chau et al. | Journal of Pediatrics | 2015
A randomized double-blind placebo-controlled Canadian trial finds that Lactobacillus reuteri DSM 17938 significantly reduces crying and fussing among breastfed infants with colic.
| G. L. Mi et al. | PLoS ONE | 2015
A randomized trial examines Lactobacillus reuteri DSM 17938 for infantile colic. Supplementation reduced daily crying duration and was associated with higher parental satisfaction compared with the control treatment.
| Hania Szajewska et al. | Journal of Pediatrics | 2013
A randomized controlled trial evaluates Lactobacillus reuteri DSM 17938 in exclusively or predominantly breastfed infants with colic. Infants receiving DSM 17938 experienced greater reductions in crying time than those receiving placebo.
| Francesco Savino et al. | Pediatrics | 2010
A randomized controlled trial administers Lactobacillus reuteri DSM 17938 to breastfed infants with colic. A dose of 100 million CFU per day reduced crying and improved colic symptoms compared with placebo.
Bifidobacterium longum 35624 — IBS
| R. Maslennikov et al. | PubMed | 2026
A strain-specific systematic review and meta-analysis identifies Bifidobacterium longum 35624, formerly classified as Bifidobacterium infantis 35624, among the individual probiotic strains showing efficacy for important IBS symptoms.
| Darren M. Brenner et al. | Reviews in Gastroenterological Disorders | 2009
A focused review examines Bifidobacterium infantis 35624 as a treatment for IBS. Two randomized controlled trials had demonstrated improvements in individual and global IBS symptoms without an apparent increase in adverse events.
| Darren M. Brenner et al. | American Journal of Gastroenterology | 2009
A systematic review of probiotics for IBS identifies Bifidobacterium infantis 35624 as one of the strains supported by appropriately designed randomized controlled studies. Trials reported improvements in abdominal pain, bloating, and bowel-related symptoms.
| Peter J. Whorwell et al. | American Journal of Gastroenterology | 2006
A large randomized controlled trial evaluates Bifidobacterium infantis 35624 in women with irritable bowel syndrome. One tested dose significantly improved abdominal pain, bloating, bowel dysfunction, incomplete evacuation, straining, and global IBS symptoms compared with placebo.
| Liam O’Mahony et al. | Gastroenterology | 2005
A randomized clinical trial compares Bifidobacterium infantis 35624 with another probiotic and placebo in IBS. Strain 35624 improved IBS symptoms and was associated with normalization of a measure of pro- versus anti-inflammatory immune signaling.
Lactiplantibacillus plantarum 299v (DSM 9843) — IBS
| H. Krammer et al. | Zeitschrift für Gastroenterologie | 2021
A clinical study evaluates Lactobacillus plantarum 299v for irritable bowel syndrome. Treatment was associated with significant improvement in global IBS symptoms and quality of life.
| C. Stevenson et al. | Nutrition | 2014
A randomized trial provides an important counterpoint to positive studies of strain 299v. Eight weeks of Lactobacillus plantarum 299v did not significantly improve abdominal pain or bloating compared with placebo, demonstrating that even a promising strain does not produce uniform results across trials.
| Philippe Ducrotté et al. | World Journal of Gastroenterology | 2012
A randomized double-blind placebo-controlled trial evaluates Lactobacillus plantarum 299v, also designated DSM 9843, in adults with IBS. Four weeks of treatment improved overall symptoms, with particularly notable reductions in abdominal pain and bloating.
| K. Niedzielin et al. | European Journal of Gastroenterology & Hepatology | 2001
An early double-blind randomized controlled trial evaluates Lactobacillus plantarum 299v in people with IBS. Participants receiving 299v reported substantially greater global improvement in IBS symptoms than those receiving placebo.
Bacillus coagulans Unique IS2 — IBS and Functional Constipation
| P. Xie et al. | Nutrients | 2023
A strain-level network meta-analysis compares individual probiotics for IBS outcomes. Bacillus coagulans Unique IS2 ranked among the strongest-performing interventions for abdominal pain.
| R. S. Madempudi et al. | Beneficial Microbes | 2020
A randomized double-blind placebo-controlled study evaluates Bacillus coagulans Unique IS2 in adults with functional constipation. Supplementation increased spontaneous bowel movements and reduced several constipation-related symptoms compared with placebo.
| R. S. Madempudi et al. | Scientific Reports | 2019
A randomized double-blind placebo-controlled trial evaluates Bacillus coagulans Unique IS2 in adults with IBS. The strain produced significant improvements in abdominal pain and several other IBS symptoms compared with placebo.
| M. Ratna Sudha et al. | Beneficial Microbes | 2018
A randomized placebo-controlled trial evaluates Bacillus coagulans Unique IS2 in children ages four through twelve with IBS. The strain significantly reduced pain intensity and improved abdominal discomfort, bloating, stool consistency, urgency, incomplete evacuation, and overall bowel satisfaction.
Bacillus coagulans MTCC 5856 — Diarrhea-Predominant IBS
| Muhammed Majeed et al. | Nutrition Journal | 2016
A randomized double-blind placebo-controlled trial evaluates Bacillus coagulans MTCC 5856 in adults with diarrhea-predominant IBS. Ninety days of supplementation improved several IBS symptoms and quality-of-life measures compared with placebo.
Bifidobacterium animalis subsp. lactis HN019 — Constipation and Gut Transit
| J. Cheng et al. | American Journal of Gastroenterology | 2024
An eight-week randomized trial further evaluates Bifidobacterium animalis subsp. lactis HN019 in adults with constipation, adding to the clinical literature concerning this strain and bowel-movement frequency.
| A. Ibarra et al. | Gut Microbes | 2018
A randomized controlled trial evaluates Bifidobacterium animalis subsp. lactis HN019 in 228 adults with functional constipation. Two daily doses were studied for effects on complete spontaneous bowel movements, stool consistency, straining, and related symptoms.
| P. A. Waller et al. | Scandinavian Journal of Gastroenterology | 2011
A randomized clinical trial examines different doses of Bifidobacterium lactis HN019. Supplementation shortened whole-gut transit time and improved the frequency of gastrointestinal symptoms.
Bifidobacterium animalis subsp. lactis BB-12 — Infantile Colic
| K. Chen et al. | Nutrients | 2021
A clinical study evaluates Bifidobacterium animalis subsp. lactis BB-12 in infants diagnosed with colic. BB-12 supplementation reduced crying and fussing.
Lactobacillus acidophilus NCFM — IBS and Functional Bowel Symptoms
| Anna Lyra et al. | World Journal of Gastroenterology | 2016
A randomized placebo-controlled study evaluates Lactobacillus acidophilus NCFM in people with irritable bowel syndrome. NCFM supplementation was associated with improvements in IBS symptom severity in some participants.
| T. Ringel-Kulka et al. | Alimentary Pharmacology & Therapeutics | 2014
A randomized clinical study examines Lactobacillus acidophilus NCFM in people with functional abdominal pain.
| T. Ringel-Kulka et al. | Journal of Clinical Gastroenterology | 2011
A randomized controlled trial evaluates Lactobacillus acidophilus NCFM together with Bifidobacterium lactis Bi-07 in patients with functional bowel disorders. The probiotic treatment significantly improved bloating compared with placebo.
Lactobacillus casei Shirota — Constipation
| A. van der Schoot et al. | Clinical Nutrition | 2022
A systematic review and meta-analysis examines individual probiotics and synbiotics for chronic constipation in adults. Lactobacillus casei Shirota was among the specifically identified strains studied.
| M. M. Araújo et al. | Nutrients | 2022
A systematic review identifies Lactobacillus casei Shirota as one of the better-studied individual strains for chronic constipation.
| Anna Chmielewska and Hania Szajewska | World Journal of Gastroenterology | 2010
A systematic review reports favorable adult evidence for Lactobacillus casei Shirota, particularly for defecation frequency and stool consistency.
Lactobacillus crispatus CTV-05 — Recurrent Urinary Tract Infection
| Matthew E. Falagas et al. | Drugs | 2006
A systematic review identifies Lactobacillus crispatus CTV-05 among strains showing promising preventive effects for recurrent urinary tract infection in women.
Lacticaseibacillus paracasei CNCM I-1518 — Respiratory and Gastrointestinal Infections
| M. Strauss et al. | Frontiers in Nutrition | 2021
A systematic review evaluates individual probiotic strains for prevention of acute respiratory tract infections. Lacticaseibacillus paracasei CNCM I-1518 is among the strains supported by randomized placebo-controlled studies.
| Theresa Poon et al. | Nutrients | 2020
A systematic review and meta-analysis of nine randomized trials evaluates a fermented dairy preparation containing Lacticaseibacillus paracasei CNCM I-1518 together with yogurt cultures.
Probiotics and Parkinson’s Disease
| X. Gu et al. | PubMed | 2025
A systematic review and meta-analysis evaluates therapies targeting the intestinal microbiota in Parkinson’s disease.
| V. Leta et al. | PubMed | 2025
A clinical study evaluates a four-strain probiotic in people with Parkinson’s disease.
| E. S. Atak et al. | PubMed / Basic and Clinical Neuroscience | 2024
A systematic review of randomized controlled trials evaluates potential therapeutic targets of probiotics in Parkinson’s disease.
| X. Jin et al. | PubMed | 2024
A systematic review and meta-analysis evaluates probiotic supplements in Parkinson’s disease.
| A. M. Mincic et al. | PubMed | 2024
A review evaluates manipulation of the intestinal microbiome in neurodegenerative disorders including Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, and amyotrophic lateral sclerosis.
| A. I. Beltrán-Velasco et al. | PubMed | 2024
A systematic review examines Lactiplantibacillus plantarum as a potential intervention for neurodegenerative diseases.
Probiotics, Alzheimer’s Disease, and Cognitive Function
| S. Tripathi et al. | PubMed | 2024
A systematic review and meta-analysis evaluates individual cognitive domains in people with mild cognitive impairment and Alzheimer’s disease.
| F. Zhu et al. | PubMed | 2024
A systematic analysis examines probiotic interventions across neurodegenerative diseases.
| R. Mo et al. | PubMed | 2024
A meta-analysis investigates probiotic supplementation in people with Alzheimer’s disease and mild cognitive impairment.
| E. Akbari et al. | Frontiers in Aging Neuroscience | 2016
A randomized double-blind controlled trial investigates probiotic supplementation in people with Alzheimer’s disease.
Probiotics and Polycystic Ovary Syndrome
| D. M. Guevara et al. | PubMed | 2024
A systematic review of randomized clinical trials evaluates probiotics, prebiotics, and synbiotics in women with polycystic ovary syndrome.
| S. Salehi et al. | PubMed | 2024
A review examines alterations of the intestinal microbiota in polycystic ovary syndrome.
| S. Alesi et al. | PubMed | 2022
A comprehensive review examines nutritional supplements and complementary therapies in PCOS.
| M. Samimi et al. | PubMed | 2019
A randomized controlled trial evaluates synbiotic supplementation in women with PCOS.
| M. Karamali et al. | PubMed | 2018
A randomized trial evaluates probiotic supplementation and hormonal profiles in women with PCOS.
| S. Ahmadi et al. | PubMed | 2017
A clinical trial examines probiotic supplementation in women with PCOS.
Probiotics and Liver Cirrhosis
| Y. L. Zhou et al. | PubMed | 2024
A meta-analysis evaluates probiotics for minimal hepatic encephalopathy.
| Y. Pan et al. | PubMed | 2024
A systematic analysis compares probiotics, prebiotics, and synbiotics for liver-related outcomes.
A systematic review evaluates probiotics in cirrhosis complicated by portal hypertension.
| Xing Yang et al. | Frontiers in Medicine | 2024
A systematic review and meta-analysis of 30 randomized studies evaluates probiotics in liver cirrhosis.
| I. D. N. Wibawa et al. | PubMed | 2023
A systematic review and meta-analysis examines probiotics for minimal hepatic encephalopathy.
| L. Huang et al. | PubMed | 2022
A review examines alterations of the intestinal microbiome in cirrhosis and the effects of probiotic supplementation.
| M. K. Lunia et al. | PubMed | 2014
A randomized controlled trial investigates probiotics for preventing hepatic encephalopathy in patients with cirrhosis.
Probiotics and Acne
| H. W. Lin et al. | PubMed | 2025
A systematic review and meta-analysis evaluates oral probiotics for acne vulgaris.
| I. A. M. P. Sutema et al. | PubMed | 2025
A systematic review examines oral and topical probiotic treatments for acne and skin health.
| A. Podwojniak et al. | PubMed | 2025
A systematic review examines acne and the cutaneous microbiome.
| A. Boby et al. | Archives of Dermatological Research | 2024
A systematic review assesses probiotics for treating acne vulgaris.
| A. Goodarzi et al. | PubMed | 2020
A review explores probiotics as adjunctive therapy for acne vulgaris.
Probiotics and Psoriasis
| Y. Gao et al. | PubMed | 2025
A review synthesizes evidence concerning intestinal dysbiosis in psoriasis and evaluates probiotics and other microbiome-directed treatments.
| Y. Zhu et al. | PubMed | 2024
A systematic review and meta-analysis evaluates probiotics as adjunctive therapy for psoriasis.
| K. Wei et al. | PubMed | 2024
A systematic review and meta-analysis evaluates probiotic supplementation for psoriasis.
| L. Zeng et al. | PubMed | 2021
A systematic review examines the effectiveness and safety of probiotic supplementation for psoriasis.
Probiotics and Allergic Rhinitis
| X. Luo et al. | PubMed | 2024
A systematic review and meta-analysis evaluates probiotics for preventing and treating allergic rhinitis in children.
| C. Luo et al. | PubMed | 2022
A systematic review and meta-analysis examines the effectiveness and safety of probiotics for allergic rhinitis.
| S. Yan et al. | PubMed | 2022
A systematic review and meta-analysis evaluates probiotics for allergic rhinitis.
| K. Farahmandi et al. | PubMed | 2022
A strain-specific systematic review evaluates probiotics for allergic rhinitis.
| A. E. Zajac et al. | PubMed | 2015
A systematic review and meta-analysis evaluates probiotics in allergic rhinitis.
Probiotics and Pediatric Asthma
| D. Fan et al. | PubMed | 2025
A systematic review evaluates probiotics, prebiotics, synbiotics, and postbiotics for pediatric asthma.
Probiotics and COVID-19
| C. H. H. Chau et al. | PubMed | 2025
A systematic review and meta-analysis evaluates probiotics for prevention and treatment of COVID-19.
| N. T. Iqbal et al. | PubMed | 2025
A review examines persistent intestinal dysbiosis associated with COVID-19 and post-COVID conditions.
| T. Amrouche et al. | PubMed | 2025
A review examines probiotic and prebiotic interventions in respiratory and viral infections.
Probiotics and Multiple Sclerosis
| Z. Zangeneh et al. | PubMed | 2025
A systematic review and meta-analysis examines probiotics in multiple sclerosis using both clinical and experimental studies.
Probiotics and Systemic Lupus Erythematosus
| L. Jin et al. | PubMed | 2025
A review explores intestinal microbiota alterations in systemic lupus erythematosus.
| Rachael Chaeh-Wen Goh et al. | PubMed | 2025
A systematic review evaluates probiotic therapy in experimental models of systemic lupus erythematosus.
Probiotics, Osteoporosis, and Bone Health
| J. N. Harini et al. | PubMed | 2025
A systematic review evaluates probiotic supplementation and bone mineral density.
| A. Ticinesi et al. | PubMed | 2025
A review examines the relationship between intestinal microbiota and bone health.
| F. Wang et al. | PubMed | 2024
A systematic review and meta-analysis examines probiotic supplementation and bone health in postmenopausal women.
Probiotics and Celiac Disease
| T. C. Scherer et al. | PubMed | 2025
A review examines mechanisms through which probiotic bifidobacteria may affect responses to gluten-derived peptides.
| F. Valitutti et al. | PubMed | 2025
A review examines intestinal microbiota in celiac disease and the possibility of personalized microbiome-directed treatment.
Probiotics and Menopausal Health
| R. A. F. Andrews et al. | PubMed | 2025
A systematic review and meta-analysis evaluates probiotics in peri- and postmenopausal women.
Probiotics and Irritable Bowel Syndrome
| B. A. Almabruk et al. | PubMed | 2024
A systematic review and meta-analysis evaluates probiotics for irritable bowel syndrome, including abdominal symptoms and quality of life.
| A. Manandhar et al. | PubMed | 2024
A systematic review examines probiotic treatment in adults with irritable bowel syndrome and inflammatory bowel disease.
| Y. Wu et al. | PubMed | 2024
A network meta-analysis compares probiotics, prebiotics, synbiotics, and fecal microbiota transplantation for IBS.
| R. Yang et al. | PubMed | 2024
A meta-analysis of 20 studies involving more than 3,000 patients evaluates the efficacy and safety of probiotics in IBS.
| V. C. Goodoory et al. | PubMed | 2023
A large systematic review and meta-analysis evaluates individual probiotic strains and combinations for IBS.
| B. Li et al. | PubMed | 2020
A systematic review and meta-analysis assesses the efficacy and safety of probiotics for IBS.
| J. R. Sun et al. | PubMed | 2020
A meta-analysis examines probiotic combinations, species, and strains used for IBS.
Probiotics and Recurrent Urinary Tract Infections
| Z. Han et al. | PubMed | 2025
A network meta-analysis evaluates non-antibiotic strategies for preventing urinary tract infections.
| M. Daniel et al. | PubMed | 2024
A double-blind randomized controlled trial evaluates Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 for preventing recurrent urinary tract infections in children.
| E. J. Nelwan et al. | PubMed | 2024
A meta-analysis evaluates probiotics as adjunctive treatments for several infectious diseases.
| V. Gupta et al. | PubMed | 2024
A randomized controlled study examines oral and vaginal probiotic prophylaxis for recurrent urinary tract infections in women.
| F. J. New et al. | PubMed | 2022
A systematic review evaluates probiotics for recurrent urinary tract infections.
| T. Akgül and B. Karakan | PubMed | 2018
A review examines the relationship between vaginal and urinary microbiota and recurrent urinary tract infection.
Probiotics and Migraine
| O. Grodzka et al. | PubMed | 2025
A clinical review examines the gut microbiota, gut-brain axis, and migraine.
| M. K. Talandashti et al. | PubMed | 2025
A systematic review and meta-analysis compares several dietary supplements used for migraine prevention.
| S. A. Tirani et al. | PubMed | 2024
A randomized clinical trial examines combined probiotic and vitamin D supplementation in people with migraine.
| H. Bazmamoum et al. | PubMed | 2024
A clinical study evaluates probiotics as an adjunct to standard migraine treatment in children.
Probiotics and Rheumatoid Arthritis
| K. Van den Bruel et al. | PubMed | 2025
A systematic review examines diets, dietary supplements, and probiotics in rheumatoid arthritis and related inflammatory disorders.
| X. E. Cheng et al. | PubMed | 2025
A systematic review evaluates nutritional supplements and dietary interventions for rheumatoid arthritis.
| W. Li et al. | PubMed | 2024
An overview of systematic reviews and meta-analyses assesses the quality of evidence supporting probiotics for rheumatoid arthritis.
| Y. Yang et al. | PubMed | 2024
A review explores the intestinal microbiome in rheumatoid arthritis and discusses probiotic treatment.
| H. C. Blenkinsopp et al. | PubMed | 2024
A review examines intestinal permeability, microbial imbalance, and rheumatoid arthritis.
| J. R. Lowe et al. | PubMed | 2020
A systematic review evaluates formulation-specific probiotic effects in inflammatory arthritis.
Probiotics and Chronic Kidney Disease
| S. Wakino et al. | PubMed | 2025
A review examines the kidney-gut axis in chronic kidney disease and microbiome-directed treatment strategies.
| K. Tsuji et al. | PubMed | 2024
A review examines the gut-kidney axis and how intestinal dysbiosis may influence chronic kidney disease.
| J. Ruszkowski et al. | PubMed | 2024
A systematic review and meta-analysis evaluates probiotic and synbiotic supplementation in chronic kidney disease.
| N. Stepanova et al. | PubMed | 2024
A review focuses on probiotic interventions among people receiving peritoneal dialysis.
| C. Liu et al. | PubMed | 2024
A systematic review and meta-analysis assesses probiotics and synbiotics in patients with chronic kidney disease.
| A. Ramezani and D. S. Raj | PubMed | 2014
A foundational review explores alterations of the intestinal microbiome in chronic kidney disease.
Probiotics and Periodontal Disease
| C. Mendonça et al. | PubMed | 2025
An umbrella review examines 30 systematic reviews concerning probiotics for periodontal and peri-implant diseases.
| N. S. Abdul et al. | PubMed | 2024
A systematic review investigates probiotics for prevention and treatment of periodontal disease.
| H. Sharma et al. | Indian Journal of Dental Research | 2024
An overview of 22 systematic reviews and meta-analyses examines probiotic supplementation for periodontal disease.
| H. Doucette et al. | PubMed | 2024
A review examines how prebiotics and probiotics may affect the oral microbiome.
| Carlota Duarte de Mendonça et al. | BMC Oral Health | 2024
A systematic review and network meta-analysis evaluates probiotics added to professional mechanical plaque removal for periodontitis.
| J. Ram et al. | PubMed | 2024
A systematic review examines Lactobacillus reuteri as an adjunct to scaling and root planing in chronic periodontitis.
| L. Puzhankara et al. | Oral Diseases | 2024
A systematic review compares probiotics with antibiotics for managing gingivitis and periodontitis.
Probiotics, Autoimmune Disease, and Inflammation
A systematic review and meta-analysis examines oral probiotic and synbiotic supplementation across autoimmune diseases.
| X. Wang et al. | PubMed | 2024
A review examines the emerging relationship between intestinal microbiota and autoimmune disease.
| L. Zeng et al. | PubMed | 2024
A systematic review and meta-analysis evaluates gut microbiota-based therapies across autoimmune diseases.
Probiotics and Kidney Stones
| H. Taheri et al. | PubMed | 2024
A review examines probiotics and herbal interventions for kidney stones and nephrolithiasis.
Probiotics and Atopic Dermatitis
| Researchers | PubMed / Springer | 2026
An umbrella review evaluates systematic reviews and meta-analyses examining probiotics for atopic dermatitis and related allergic conditions in infants and children.
| Researchers | Journal of Allergy and Clinical Immunology: Global | 2026
A systematic review and meta-analysis examines randomized trials of probiotics for eczema and atopic dermatitis in children and adolescents.
| Researchers | Indian Journal of Dermatology | 2025
A systematic review and meta-analysis examines probiotic supplementation for adults with atopic dermatitis.
A systematic review and meta-analysis evaluates probiotic supplementation in adults with atopic dermatitis.
| Researchers | Pediatric Allergy and Immunology | 2020
A network meta-analysis compares different probiotic strains used to treat pediatric atopic dermatitis.
Probiotics and Helicobacter pylori
| Researchers | Microbial Pathogenesis | 2026
A meta-analysis of 28 randomized controlled trials evaluates probiotic monotherapy for reducing Helicobacter pylori colonization without antibiotics.
Probiotics and Oral Health
| Researchers | Frontiers in Oral Health | 2026
An umbrella review of meta-analyses examines probiotic interventions for dental and oral health.
A systematic review evaluates randomized clinical trials investigating probiotics for enamel demineralization and cariogenic bacteria.
A systematic review investigates probiotics and oral health, including dental caries, periodontal disease, halitosis, mucositis and peri-implant conditions.
Probiotics and Obesity, Cholesterol, and Metabolic Health
| Researchers | Obesity Reviews | 2026
A systematic review and meta-analysis examines probiotic and synbiotic supplementation and lipid levels among people with overweight and obesity.
| Researchers | Diabetes & Metabolic Syndrome | 2024
A systematic review and meta-analysis evaluates probiotics, prebiotics, synbiotics and other microbiome-modifying therapies for metabolic syndrome.
| Researchers | Clinical Nutrition | 2021
A meta-analysis of 26 randomized controlled trials involving 1,720 participants evaluates probiotics for people with overweight or obesity.
A systematic review and meta-analysis examines probiotic and synbiotic supplementation in adults with metabolic syndrome.
| Researchers | Current Atherosclerosis Reports | 2020
A systematic review and meta-analysis examines probiotics and cardiovascular disease risk factors.
A systematic review and meta-analysis examines probiotics for overweight and obesity.
Probiotics and Fatty Liver Disease
A network meta-analysis compares different probiotic combinations for nonalcoholic fatty liver disease.
| Researchers | Expert Review of Gastroenterology & Hepatology | 2022
A systematic review and meta-analysis evaluates randomized controlled trials of probiotics for nonalcoholic fatty liver disease.
An early meta-analysis examines probiotic treatment for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Probiotics and Constipation
| Researchers | Nutrients | 2022
A systematic review and meta-analysis examines probiotics for constipation-predominant irritable bowel syndrome.
A systematic review and meta-analysis examines probiotic products for constipation in adults.
| Researchers | American Journal of Clinical Nutrition | 2014
A systematic review and meta-analysis evaluates probiotics for functional constipation in adults.
Probiotics and Bacterial Vaginosis
A systematic review and meta-analysis evaluates probiotics for bacterial vaginosis.
| Researchers | European Journal of Pharmacology | 2019
A systematic review and meta-analysis of 13 randomized clinical trials evaluates probiotics alone and in combination with antibiotics for bacterial vaginosis.